References
- 1. Irvine AD, Mellerio JE. Genetics and genodermatoses. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s textbook of dermatology. 8th ed. Oxford: Blackwell Publishing Ltd; 2010. p. 15.1-15.97.10.1002/9781444317633.ch15
- 2. Sehgal VN, Verma P, Chatterjee K. Type 1 neurofibromatosis (von Recklinghausen disease). Cutis 2015;96(3):E23-6.
- 3. von Recklinghausen F. Uber die Multiplen Fibrome der Haut und Ihre Beziehung Zu Den Multiplen Neuromen. Berlin: August Hirschwald; 1882.
- 4. Crowe FW, Schull WJ, Neel JV. A clinical, pathological and genetic study of multiple neurofibromatosis. Springfield, IL: Charles C Thomas; 1956.
- 5. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;1(1):1–16.10.1016/j.jaad.2008.12.051271654619539839
- 6. Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178(5):1932–9.10.1016/j.ajpath.2010.12.056308115721457932
- 7. Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics 2011;5(6):623–90.10.1186/1479-7364-5-6-623352524622155606
- 8. Diggs-Andrews KA, Gutmann DH. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci 2013;36(4):237–47.10.1016/j.tins.2012.12.002362280923312374
- 9. Fox CJ, Tomajian S, Kaye AJ, Russo S, Abadie JV, Kaye AD. Perioperative management of neurofibromatosis type 1. Ochsner J 2012;12(2):111–21.
- 10. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44(2):81–8.10.1136/jmg.2006.045906259806317105749
- 11. Gabriele AL, Ruggieri M, Patitucci A, Magariello A, Conforti FL, Mazzei R, et al. A novel NF1 gene mutation in an Italian family with neurofibromatosis type 1. Childs Nerv Syst 2011;27(4):635-8.10.1007/s00381-010-1282-z20927530
- 12. Allouche J, Bellon N, Saidani M, Stanchina-Chatrousse L, Masson Y, Patwardhan A, et al. In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells. Proc Natl Acad Sci USA 2015;112(29):9034–9.10.1073/pnas.1501032112451723526150484
- 13. Shah KN. The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am 2010;57(5):1131-53.10.1016/j.pcl.2010.07.00220888463
- 14. Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C. Plexiform neurofibroma- a case report. Medicine (Baltimore) 2016;95(6):e2663.10.1097/MD.0000000000002663475388826871793
- 15. Staser K, Yang FC, Clapp DW. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu Rev Pathol 2012;7:469–95.10.1146/annurev-pathol-011811-132441369473822077553
- 16. O’Brien DE, Brenner DS, Gutmann DH, Gereau RW. Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. J Pain 2013;14(6):628–37.10.1016/j.jpain.2013.01.770367224023578956
- 17. Korf BR. Statins, bone, and neurofibromatosis type 1. BMC Med 2008;6:2210.1186/1741-7015-6-22253112818671845
- 18. Arun KP, Joseph T, Jaishankar HP, Abhinethra MS. Von Recklinghausens disease: a series of four cases with variable expression. J Maxillofac Oral Surg 2015;14(1):161–7.10.1007/s12663-012-0399-x437927225838692
- 19. Rodriguez FJ, Perry A, Gutmann DH, O’Neill BP, Leonard J, Bryant S, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67(3):240–9.10.1097/NEN.0b013e318165eb75341706418344915
- 20. Klein-Tasman BP, Janke KM, Luo WL, Casnar CL, Hunter SJ, Tonsgard JT, et al. Cognitive and psychosocial phenotype of young children with neurofibromatosis-1. J Int Neuropsychol Soc 2014;20(1):88–98.10.1017/S1355617713001227424994324229851
- 21. Gutmann DH, Parada LF, Silva Aj, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci 2012;32(41):14087–93.10.1523/JNEUROSCI.3242-12.2012347784923055477
- 22. Madubata CC, Olsen MA, Stwalley DL, Gutmann DH, Johnson KJ. Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis. Genet Med 2015;17(1):36–42.10.1038/gim.2014.70425789524901347
- 23. Licis AK, Vallorani A, Gao F, Chen C, Lenox J, Yamada KA, et al. Prevalence of sleep disturbances in children with neurofibromatosis type 1. J Child Neurol 2013;28(11):1400–5.10.1177/0883073813500849380576324065580
- 24. Agaimy A, Vassos N, Croner RS. Gastrointestinal and retroperitoneal manifestations of neurofibromatosis type 1 (Recklinghausen’s disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 2012;5(9):852–62.
- 25. Salvi P, Lorenzon L, Caterino S, Antolino L, Antonelli MS, Balducci G. Gastrointestinal stromal tumors associated with neurofibromatosis 1: a single centre experience and systematic review of the literature including 252 cases. Int J Surg Oncol 2013;2013:398570.10.1155/2013/398570387228024386562
- 26. Hersh JH. Health supervision for children with neurofibromatosis. Pediatrics 2008;121(3):633–4210.1542/peds.2007-336418310216
- 27. Zografos GN, Vasiliadis GK, Zagouri F, Aggeli C, Korkolis D, Vogiaki S, et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol 2010;8:14.10.1186/1477-7819-8-14284813420219130
- 28. Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab 2010;24(3):439–49.10.1016/j.beem.2010.02.002293906120833335
- 29. Cunha KS, Rozza-de-Menezes RE, Luna EB, Almeida LM, Pontes RR, Almeida PN, et al. High prevalence of hyposalivation in individuals with neurofibromatosis 1: a case–control study. Orphanet J Rare Dis 2015;10:24.10.1186/s13023-015-0239-4435192725759173
- 30. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4(3):105–11.10.1097/00125817-200205000-0000212180143
- 31. Oderich GS, Sullivan TM, Bower TC, Gloviczki P, Miller DV, Babovic-Vuksanovic D, et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. J Vasc Surg 2007;46(3):475–84.10.1016/j.jvs.2007.03.05517681709
- 32. Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis 2011;6:18.10.1186/1750-1172-6-18309553521542925
- 33. Park SJ, Sawitzki B, Kluwe L, Mautner V, Holtkamp N, Kurtz A. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med 2013;11:109.10.1186/1741-7015-11-109364845523618374
- 34. Karajannis MA, Ferner RE. Neurofibromatosis–related tumors: emerging biology and therapies. Curr Opin Pediatr 2015;27(1):26–33.10.1097/MOP.0000000000000169437413225490687
- 35. Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006;95(2):233–8.10.1038/sj.bjc.6603227236061616786042